AI Article Synopsis
- Recombinant adenoviruses are increasingly used in vaccine development and gene therapy, leading to the creation of molecular assays for measuring adenoviral particles and their infectious strength.
- The Genome Quantitation Assay (GQA) and QPCR-Based Potency Assay (QPA) are precise and rapid methods that can be performed manually or with automated systems for efficient processing.
- These assays allow for detailed product characterization and release, and can quantify viral replication without relying on cell damage, enabling better assessment of adenoviral serotypes in vaccines.
Article Abstract
The broad application of recombinant adenoviruses to the development of vaccines and gene therapy vectors has encouraged the development of molecular assays for the facile quantitation of adenoviral particles and the assignment of their infectious potency. The Genome Quantitation Assay (GQA) and the QPCR-Based Potency Assay (QPA) developed for adenoviruses offer the attributes of precision, rapidity, and high throughput either performed manually or facilitated by simple automated liquid handling systems. These assay attributes allow for accelerated process development support and product characterization and release. The assays for adenovirus could offer the additional advantage in that their quantitation is based on viral replication independent of cytopathology permitting quantitation of serotypes that cause minimal cytopathic effect (CPE) in 293 cells and specificity that allows the components of multivalent vaccines to be discriminated and quantitated for release.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-1-60327-248-3_3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!